Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05916755

Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform

Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Triple Negative Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases Triple Negative Breast Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Vall d'Hebron Institute of Oncology

Barcelona, 08035, Spain

Location status: Recruiting

Location contact

Mafalda Oliveira, MD PhD

CONTACT

[email protected]

+34932543450

About this study

The combination of pembrolizumab, an immune checkpoint inhibitor (ICI), with neoadjuvant chemotherapy (NACT) increases pathologic complete response (pCR) and event-free survival (EFS) in patients with early triple negative breast cancer (eTNBC). However, not all patients equally benefit from a treatment that may have relevant adverse events (AEs).

Objectives: (1) To establish predictive biomarkers of response to NACT + ICI in eTNBC by correlating data coming from different layers of omics performed in different tissues, together with imaging, with pCR, EFS, and overall survival (OS). (2) To integrate data generated from (1), and clinical data, and explore multivariate predictive models of response to NACT + ICI.

Methods: Patients with stage II-III TNBC candidates to receive NACT +/- ICI will be included. Collected samples and type of analysis: (1) Tumor tissue (baseline and from residual disease after NACT): whole genome sequencing (WGS) and RNA-Seq will be performed (Hartwig sequencing platform and analytical pipeline), tissue immune phenotyping (PD-L1, T and B infiltrating lymphocytes, among others), and microbiome analysis (16S rRNA); (2) Blood (before and during NACT): circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS), T-cell receptor beta (TCR-β) repertoire sequencing and analysis (ImmunoSeq hsTCRβ kit and immunoSEQ), and peripheral blood mononuclear cells (PBMCs) phenotyping; (3) Stools and saliva (before and during NACT): microbiome analysis (16S rRNA); (4) Breast MRI imaging (before and after NACT): radiomics analysis. Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs. The aim is to provide more personalized treatment efficacy and risk for relapse estimates.

Expected outcome: To develop a clinical tool to assist clinicians in the process of treatment decision-making in eTNBC, in order to maximize patient's benefit and quality of life, while minimizing AEs and financial burden to the health system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically documented TNBC (negative human epidermal growth factor receptor 2 [HER2], estrogen receptor [ER], and progesterone receptor [PgR] status)
  • Stage 2 - 3 defined by the American Joint Committee of Cancer (AJCC) staging criteria 8th edition for breast cancer as assessed by the investigator based on radiological and/or clinical assessment
  • Patient is a candidate to receive NACT with or without ICI as assessed by the investigator
  • Patient is ≥ 18 years old at the time of consent to participate in this trial

Exclusion criteria

  • Metastatic disease on imaging (stage 4)

Treatment and study plan

Whole genome sequencing

Diagnostic Test

Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.

Other names: WGS

RNA-Sequencing

Diagnostic Test

RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).

Microbiome analysis

Diagnostic Test

Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.

ctDNA analysis

Diagnostic Test

ctDNA analysis will be performed in plasma before and during NACT.

TCR-β repertoire sequencing

Diagnostic Test

TCR-β repertoire sequencing will be performed in plasma before and during NACT.

PBMCs phenotyping

Diagnostic Test

PBMCs phenotyping will be performed in plasma before and during NACT.

Pembrolizumab

Drug

Pembrolizumab will be given in combination with standard NACT.

Chemotherapy

Drug

Standard NACT will be given.

Other names: Carboplatin, taxane, anthracycline, cyclophosphamide

Primary outcomes

  1. Pathologic complete response (pCR) rate at definitive surgery

    Time frame: after neoadjuvant treatment and surgery, up to approximately 27-30 weeks

    The rate (given as a percentage) of patients with a pCR at definitive surgery using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) from the American Joint Committee on Cancer (AJCC) staging criteria

  2. Event-free survival (EFS)

    Time frame: Up to approximately 60 months

    EFS is defined as the time from the start of neoadjuvant treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause

  3. Overall survival (OS)

    Time frame: Up to approximately 60 months

    OS is defined as the time from starting neoadjuvant treatment until death due to any cause

  4. Identification of biomarkers to predict clinical outcomes (pCR at definitive surgery, EFS, OS).

    Time frame: After all data are analyzed, up to approximately 60 months

    The clinical data (pCR at definitive surgery, EFS, OS) will be integrated with the results from the multiomics platform and multivariate predictive models of response to neoadjuvant chemotherapy (NACT) + immune checkpoint inhibitor (ICI) will be explored. Precisely, the multiomics platform will analyze:

    • RNA-Sequencing of the initial tumor and residual disease (if present)
    • microbiome analysis of the saliva and feces,
    • circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS),
    • Tissue immune phenotyping,
    • T-cell receptor beta (TCR-β) repertoire sequencing and analysis using ImmunoSeq hsTCRβ kit and immunoSEQ,
    • Breast MRI imaging (before and after NACT),

    Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs.

Sponsors and collaborators

Lead sponsor

Vall d'Hebron Institute of Oncology

Other

Registry information

Official study title

Identification of Predictive Biomarkers of Response to Chemotherapy and Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: an Integrative Multiomics Platform

Acronym: PORTRAIT

Important dates

Study start
2023
Primary completion
2026
Study completion
2029
First posted
Jun 23, 2023
Registry last updated
Jun 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.